Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Some tax loss selling to pick uo some .38
ALIM bid ask all over the place too.
No delay paid by company
If not its bad. Hoping 5
If not its bad. Hoping 5
Looka a lot lie arna on pfuda date
hoping for a bear raid and then see the shorts cover. That would me make me more optimistic on chances of approval. I am not sure this goes much higher than 7 initially if approved.
PSDV will be interesting to see price action today.
he is one of the few guys I follow on Seeking Alpha link
http://seekingalpha.com/article/1733322-psivida-previewing-the-possible-effect-on-the-stock-of-the-october-17th-pdufa-date-for-iluvien
he is one of the few guys I follow on Seeking Alpha link
http://seekingalpha.com/article/1733322-psivida-previewing-the-possible-effect-on-the-stock-of-the-october-17th-pdufa-date-for-iluvien
Smith on Stocks has a target of 9 to 13 with approval. Beginning to think if approved will be happy with 7 or 8 immediately post approval.
psdv was dropped yesterday and ALIM traded in a pretty tight range. Leads me to believe that there was a lot of manipulation going on with PSDV. Closing in on PDUFA.
Alim did not move too much at all today. Scare tactics. This will move back up b4 pdufa
AGEN late news
GSK's Vaccine Candidate Containing Agenus' QS-21 Stimulon(R) Reduces Malaria Infection in Phase 3 Trials of Over 15,000 Children
13 hours 38 minutes ago - DJNF
-- Significant protection shown 18 months post vaccination
-- RTS,S vaccine could have a major public health impact on malaria in
Africa
-- GSK plans regulatory submission in 2014
-- Agenus entitled to receive milestone payment and royalties upon launch
LEXINGTON, Mass.--(BUSINESS WIRE)--October 07, 2013--
Agenus Inc. (NASDAQ: AGEN) today announced that new Phase 3 data for GlaxoSmithKline's (NYSE: GSK) RTS,S malaria vaccine candidate, which contains Agenus' QS-21 Stimulon(R)1 adjuvant, were presented at a Multilateral Initiative on Malaria Pan African Conference in Durban, South Africa. The abstract and presentation titled, "Efficacy of RTS, S/AS01 vaccine candidate against malaria in African infants and children 18 months post-primary vaccination series: a Phase 3 randomized, double-blind controlled trial," shows that RTS,S helped protect young children and infants from clinical malaria up to 18 months post vaccination. RTS,S is the most advanced malaria vaccine candidate in the world and the first vaccine candidate to show in clinical trials that it can help protect young children and infants living in malaria-endemic areas against clinical disease and infection caused by Plasmodium falciparum. Malaria claims over 600,000 lives a year, most of which are children in Sub-Saharan Africa.(2)
"These findings indicate that RTS,S has the potential to help prevent millions of malaria cases. We are very pleased that our QS-21 Stimulon adjuvant is a key component of AS01, a proprietary adjuvant system used in RTS,S," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus Inc. "These results provide further support that QS-21 Stimulon can help advance challenging development programs targeting difficult diseases. Currently there are 21 development programs underway involving vaccines that include QS-21 Stimulon for many different types of cancer, infectious diseases and degenerative disorders."
RTS,S Efficacy
For the first time, the efficacy of the vaccine candidate was assessed at each trial site separately, which are in regions with different levels of malaria disease. Efficacy was found to be statistically significant at all sites in young children and at four sites in infants.
According to the results, children aged 5-17 months at first vaccination with RTS,S experienced 46% fewer cases of clinical malaria, compared to children immunized with a control vaccine. Recognizing that children can each be affected by more than one case of malaria, this results in 941 cases of clinical malaria prevented over 18 months of follow-up for every 1,000 children vaccinated. Severe malaria cases were reduced by 36%, resulting in 21 cases of severe malaria prevented over 18 months of follow-up for every 1,000 children vaccinated. Malaria hospitalizations were reduced by 42%. These results in children 5-17 months were statistically significant.
Infants aged 6-12 weeks at first vaccination with RTS,S had 27% fewer cases of clinical malaria, resulting in 444 cases of clinical malaria prevented over 18 months of follow-up for every 1,000 infants vaccinated. The reduction of severe malaria cases and malaria hospitalizations by 15% and 17%, respectively, were not statistically significant.
The reduction in number of malaria cases attributed to RTS,S was demonstrated in addition to the effect of existing malaria control measures such as insecticide treated bed nets that were used by 78% of children and 86% of infants in the trial.
Previous results from one year follow-up of the Phase 3 trial showed that efficacy of RTS,S was 56% against clinical malaria and 47% against severe malaria for the 5-17 month-old age group and 31% against clinical malaria and 37% against severe malaria in the 6-12 week-old age group.
RTS,S continued to display an acceptable safety and tolerability profile during the 18 month follow-up. No new safety signals were observed during this longer follow-up period. The incidence of severe adverse events overall was similar in participants in each group but the imbalance in reported cases of meningitis, noted previously(3) , has persisted.
Further data from 32 months follow-up and the impact of a 'booster' dose given after 18 months are expected to become available in 2014.
About RTS,S
RTS,S is a scientific name given to this malaria vaccine candidate and represents the composition of this vaccine candidate that also contains the AS01 adjuvant system.(4) RTS,S aims to trigger the immune system to defend against the Plasmodium falciparum malaria parasite when it first enters the human host's bloodstream and/or when the parasite infects liver cells. It is designed to prevent the parasite from infecting, maturing, and multiplying in the liver, after which time the parasite would re-enter the bloodstream and infect red blood cells, leading to disease symptoms.
These new data support GSK's plans to submit a regulatory application in 2014 for a Scientific Opinion of the European Medicines Agency (EMA) on RTS,S safety, efficacy and quality. If the EMA give a positive opinion, and there is satisfactory public health information from the Phase 3 program, the World Health Organization has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible in 2015, paving the way for potential decisions by African nations for large-scale implementation of the vaccine through their national immunization programs.
About GlaxoSmithKline
GSK is one of the world's leading research-based pharmaceutical and healthcare companies and committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information about the RTS,S program, please visit www.gsk.com.
About Agenus' QS-21 Stimulon(R) Adjuvant
Agenus' flagship adjuvant, QS-21 Stimulon adjuvant, is a saponin extracted from the bark of the Quillaja saponaria tree, also known as the soap bark tree or Soapbark, an evergreen tree native to warm temperate central Chile. Agenus' GMP QS-21 Stimulon has become a key component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases, and appears to be essential for several investigational therapeutic vaccines intended to treat cancer and degenerative disorders. QS-21 Stimulon has been widely studied and approximately 50,000 patients have received vaccines containing the adjuvant. QS-21 Stimulon is being studied in 21 vaccine indications, which include GSK's Phase 3 vaccine programs for RTS,S for malaria, MAGE-A3 cancer immunotherapeutic for non-small cell lung cancer and melanoma and HZ/su for shingles. In addition, Janssen's QS-21 Stimulon adjuvant-containing vaccine candidate is in Phase 2 trials for the treatment of Alzheimer's disease, and Agenus' HerpV, a therapeutic vaccine for the treatment of genital herpes, is in a Phase 2 trial. Agenus is generally entitled to receive milestone payments as QS-21 Stimulon containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
About Agenus
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Between Agenus and its partners, 23 programs are in clinical development. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.
1. QS-21 Stimulon(R) adjuvant and the related agreements, and HerpV are assets of Antigenics Inc., a wholly owned subsidiary of Agenus Inc.
2. http://www.who.int/malaria/world_malaria_report_2011/en/index.html
3. The RTS,S Clinical Trials Partnership. NEJM. 2011; DOI 10.1056/NEJMoa1102287; The RTS,S Clinical Trials Partnership. NEJM. 2012; DOI: 10.1056/NEJMoa1208394
4. The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon(R) adjuvant, MPL and liposomes. Stimulon is a registered trademark of Agenus Inc. and its subsidiaries.
Forward-Looking Statement
This press release contains forward-looking statements, including statements regarding the potential application product candidates containing the Company's QS-21 Stimulon Adjuvant in the prevention and treatment of diseases, and revenue streams to Agenus in connection therewith. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2013. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus' business and securities, investors should give careful consideration to these risks and uncertainties.
CONTACT: Media and Investor Contact:
Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and
Corporate Communications
jonae.barnes@agenusbio.com
SOURCE: Agenus Inc.
Copyright Business Wire 2013
Order free Annual Report for Agenus, Inc.
Visit http://djnweurope.ar.wilink.com/?ticker=US00847G7051 or call +44 (0)208 39
AGEN
GSK's Vaccine Candidate Containing Agenus' QS-21 Stimulon(R) Reduces Malaria Infection in Phase 3 Trials of Over 15,000 Children
13 hours 38 minutes ago - DJNF
-- Significant protection shown 18 months post vaccination
-- RTS,S vaccine could have a major public health impact on malaria in
Africa
-- GSK plans regulatory submission in 2014
-- Agenus entitled to receive milestone payment and royalties upon launch
LEXINGTON, Mass.--(BUSINESS WIRE)--October 07, 2013--
Agenus Inc. (NASDAQ: AGEN) today announced that new Phase 3 data for GlaxoSmithKline's (NYSE: GSK) RTS,S malaria vaccine candidate, which contains Agenus' QS-21 Stimulon(R)1 adjuvant, were presented at a Multilateral Initiative on Malaria Pan African Conference in Durban, South Africa. The abstract and presentation titled, "Efficacy of RTS, S/AS01 vaccine candidate against malaria in African infants and children 18 months post-primary vaccination series: a Phase 3 randomized, double-blind controlled trial," shows that RTS,S helped protect young children and infants from clinical malaria up to 18 months post vaccination. RTS,S is the most advanced malaria vaccine candidate in the world and the first vaccine candidate to show in clinical trials that it can help protect young children and infants living in malaria-endemic areas against clinical disease and infection caused by Plasmodium falciparum. Malaria claims over 600,000 lives a year, most of which are children in Sub-Saharan Africa.(2)
"These findings indicate that RTS,S has the potential to help prevent millions of malaria cases. We are very pleased that our QS-21 Stimulon adjuvant is a key component of AS01, a proprietary adjuvant system used in RTS,S," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus Inc. "These results provide further support that QS-21 Stimulon can help advance challenging development programs targeting difficult diseases. Currently there are 21 development programs underway involving vaccines that include QS-21 Stimulon for many different types of cancer, infectious diseases and degenerative disorders."
RTS,S Efficacy
For the first time, the efficacy of the vaccine candidate was assessed at each trial site separately, which are in regions with different levels of malaria disease. Efficacy was found to be statistically significant at all sites in young children and at four sites in infants.
According to the results, children aged 5-17 months at first vaccination with RTS,S experienced 46% fewer cases of clinical malaria, compared to children immunized with a control vaccine. Recognizing that children can each be affected by more than one case of malaria, this results in 941 cases of clinical malaria prevented over 18 months of follow-up for every 1,000 children vaccinated. Severe malaria cases were reduced by 36%, resulting in 21 cases of severe malaria prevented over 18 months of follow-up for every 1,000 children vaccinated. Malaria hospitalizations were reduced by 42%. These results in children 5-17 months were statistically significant.
Infants aged 6-12 weeks at first vaccination with RTS,S had 27% fewer cases of clinical malaria, resulting in 444 cases of clinical malaria prevented over 18 months of follow-up for every 1,000 infants vaccinated. The reduction of severe malaria cases and malaria hospitalizations by 15% and 17%, respectively, were not statistically significant.
The reduction in number of malaria cases attributed to RTS,S was demonstrated in addition to the effect of existing malaria control measures such as insecticide treated bed nets that were used by 78% of children and 86% of infants in the trial.
Previous results from one year follow-up of the Phase 3 trial showed that efficacy of RTS,S was 56% against clinical malaria and 47% against severe malaria for the 5-17 month-old age group and 31% against clinical malaria and 37% against severe malaria in the 6-12 week-old age group.
RTS,S continued to display an acceptable safety and tolerability profile during the 18 month follow-up. No new safety signals were observed during this longer follow-up period. The incidence of severe adverse events overall was similar in participants in each group but the imbalance in reported cases of meningitis, noted previously(3) , has persisted.
Further data from 32 months follow-up and the impact of a 'booster' dose given after 18 months are expected to become available in 2014.
About RTS,S
RTS,S is a scientific name given to this malaria vaccine candidate and represents the composition of this vaccine candidate that also contains the AS01 adjuvant system.(4) RTS,S aims to trigger the immune system to defend against the Plasmodium falciparum malaria parasite when it first enters the human host's bloodstream and/or when the parasite infects liver cells. It is designed to prevent the parasite from infecting, maturing, and multiplying in the liver, after which time the parasite would re-enter the bloodstream and infect red blood cells, leading to disease symptoms.
These new data support GSK's plans to submit a regulatory application in 2014 for a Scientific Opinion of the European Medicines Agency (EMA) on RTS,S safety, efficacy and quality. If the EMA give a positive opinion, and there is satisfactory public health information from the Phase 3 program, the World Health Organization has indicated that a policy recommendation for the RTS,S malaria vaccine candidate is possible in 2015, paving the way for potential decisions by African nations for large-scale implementation of the vaccine through their national immunization programs.
About GlaxoSmithKline
GSK is one of the world's leading research-based pharmaceutical and healthcare companies and committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information about the RTS,S program, please visit www.gsk.com.
About Agenus' QS-21 Stimulon(R) Adjuvant
Agenus' flagship adjuvant, QS-21 Stimulon adjuvant, is a saponin extracted from the bark of the Quillaja saponaria tree, also known as the soap bark tree or Soapbark, an evergreen tree native to warm temperate central Chile. Agenus' GMP QS-21 Stimulon has become a key component in the development of investigational preventive vaccine formulations across a wide variety of infectious diseases, and appears to be essential for several investigational therapeutic vaccines intended to treat cancer and degenerative disorders. QS-21 Stimulon has been widely studied and approximately 50,000 patients have received vaccines containing the adjuvant. QS-21 Stimulon is being studied in 21 vaccine indications, which include GSK's Phase 3 vaccine programs for RTS,S for malaria, MAGE-A3 cancer immunotherapeutic for non-small cell lung cancer and melanoma and HZ/su for shingles. In addition, Janssen's QS-21 Stimulon adjuvant-containing vaccine candidate is in Phase 2 trials for the treatment of Alzheimer's disease, and Agenus' HerpV, a therapeutic vaccine for the treatment of genital herpes, is in a Phase 2 trial. Agenus is generally entitled to receive milestone payments as QS-21 Stimulon containing programs advance, as well as royalties for 10 years after commercial launch, with some exceptions.
About Agenus
Agenus Inc. is a biotechnology company working to develop treatments for cancers and infectious diseases. The company is focused on immunotherapeutic products based on strong platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Between Agenus and its partners, 23 programs are in clinical development. For more information, please visit www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter and Google+.
1. QS-21 Stimulon(R) adjuvant and the related agreements, and HerpV are assets of Antigenics Inc., a wholly owned subsidiary of Agenus Inc.
2. http://www.who.int/malaria/world_malaria_report_2011/en/index.html
3. The RTS,S Clinical Trials Partnership. NEJM. 2011; DOI 10.1056/NEJMoa1102287; The RTS,S Clinical Trials Partnership. NEJM. 2012; DOI: 10.1056/NEJMoa1208394
4. The GSK proprietary AS01 adjuvant system contains QS-21 Stimulon(R) adjuvant, MPL and liposomes. Stimulon is a registered trademark of Agenus Inc. and its subsidiaries.
Forward-Looking Statement
This press release contains forward-looking statements, including statements regarding the potential application product candidates containing the Company's QS-21 Stimulon Adjuvant in the prevention and treatment of diseases, and revenue streams to Agenus in connection therewith. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission for the period ended June 30, 2013. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Agenus undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Agenus' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Agenus' business and securities, investors should give careful consideration to these risks and uncertainties.
CONTACT: Media and Investor Contact:
Agenus Inc.
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations and
Corporate Communications
jonae.barnes@agenusbio.com
SOURCE: Agenus Inc.
Copyright Business Wire 2013
Order free Annual Report for Agenus, Inc.
Visit http://djnweurope.ar.wilink.com/?ticker=US00847G7051 or call +44 (0)208 39
Hoping they get an extension by NYSE. This should alleviate some of the financial concerns:
NEWARK, Del., June 5, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that on May 31, 2013, the NYSE MKT (the "Exchange") notified the Company that it accepted the Company's Plan of Compliance and granted the Company an extension until October 14, 2013 to regain compliance with the continued listing requirements of the Exchange. On April 18, 2013, the Company received notice from NYSE MKT Staff indicating that the Company was below certain of the Exchange's continued listing standards set forth in Section 1003(iv), which applies if a listed company has sustained losses that are so substantial in relation to its overall operations or its existing financial resources, or its financial condition has become so impaired that it is questionable, in the opinion of the Exchange, as to whether the listed company will be able to continue its operations or meet its obligations as they mature
decision 2014 is key here
IBIO - looking for a quick 10 percent pop or more today. need to meet requirements or get extension oct 16th
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement
Amendment of TTA between iBio and Fraunhofer
We and Fraunhofer, USA, Inc. ("Fraunhofer"), our collaborative research and development partner, entered into a new agreement effective June 30, 2013 (the "2013 Amendment") that has the effect of further amending the terms of the Technology Transfer Agreement which we and Fraunhofer originally entered into effective as of January 1, 2004 (as previously amended, the "TTA"). The 2013 Amendment, which is intended to better align the mutual interests of iBio and Fraunhofer, has the following effects:
? Our liabilities to Fraunhofer in the amount of approximately $2,863,000 as of June 30, 2013 were released and terminated.
? The term of the TTA was extended by one year and will now expire on December 31, 2015.
? Our obligation under the TTA, prior to the 2013 Amendment, to make three further time-based $1,000,000 payments, on April 2 and November 2, 2013 and April 2, 2014 ("Guaranteed Annual Payments") was terminated and replaced with an obligation to engage Fraunhofer in iBio selected and directed project specific development activities, priced according to a mutually-agreed fair market formula, in an aggregate amount not less than $3,000,000 prior to December 31, 2015. We believe that our right to select and direct specific projects will improve the efficiency of our product development activities and that the extension of the period over which this commitment must be fulfilled will enhance our ability to manage our cash outflow.
? We terminated and released Fraunhofer from the obligation to make further financial contributions toward the enhancement, improvement and expansion of our technology in an amount at least equal to the Guaranteed Annual Payments, because we believe our technology development phase is completed and now are focusing on product development. Additionally, we terminated and released Fraunhofer from the obligation to further reimburse us for certain past and future patent related expenses.
Up we go today. I do not think they would have received extension in spring unless they gave some type of info that warranted it.
iBio, Inc. (NYSE MKT: IBIO), a leading provider of technology for both proprietary and biosimilar products for use in development and production of biologics, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San Francisco.
Believe there will be a run up before they have to answer listing requirement.
Sa article: 8-15-13
http://seekingalpha.com/article/1636912-merrimack-undervalued-because-of-misunderstanding-and-miscommunication?source=yahoo
http://finance.yahoo.com/q/ao?s=MACK+Analyst+Opinion
Recommendation Summary*
Mean Recommendation (this week): 1.9
Mean Recommendation (last week): 1.4
Change: 0.5
* (Strong Buy) 1.0 - 5.0 (Sell)
Price Target Summary
Mean Target: 10.20
Median Target: 10.00
High Target: 14.00
Low Target: 6.00
No. of Brokers: 5
dilution? I did not realize that they have 31 mil on hand but have to pay 25 mil to psdv when/if approved. Still think this is gonna run and bounce so good point to buy.
ALIM also related to PSDV hopefully will bounce a litlle
Lots of support .83 & .85.
Well at least I'm excited about 1 of my holdings tomorrow. Looks like I may be adding.
Would not be surprised if we hit 70's within a week.
looks like you were dead on. Hoping for that bounce mid next week.
CPRX Will their notice of 180 extension come out on Monday or will they first receive an additional deficiency notice?
CPRX updated presentation June 17th Firdapse link:
http://files.shareholder.com/downloads/CPRX/2535914370x0x671247/ebace63b-9002-4a51-bdd4-783f9aef298a/CPRX130613.pdf
On June 17, 2013, the Company updated its corporate presentation materials on its website. The updated presentation, which is available on the “Events and Presentations” page on the Company’s website at http://ir.catalystpharma.com/events.cfm, provides the most updated information about the status of the Company’s Phase III clinical trial evaluating Firdapse™ for the treatment of Lambert-Eaton Myasthenic Syndrome.
Cprx updated presentation
http://files.shareholder.com/downloads/CPRX/2535914370x0x671247/ebace63b-9002-4a51-bdd4-783f9aef298a/CPRX130613.pdf
On June 17, 2013, the Company updated its corporate presentation materials on its website. The updated presentation, which is available on the “Events and Presentations” page on the Company’s website at http://ir.catalystpharma.com/events.cfm, provides the most updated information about the status of the Company’s Phase III clinical trial evaluating Firdapse™ for the treatment of Lambert-Eaton Myasthenic Syndrome.
CPRX - Is it basically a forgone conclusion that this will receive a 180 day delisting extension next week?? I am thinking of adding in increments trying to catch bottom on the dip, without putting to much of my portfolio in one play. Thanks!!!
Norm
will not get delisted even if falls short.
Under the Rules, the Company has a grace period of 180 days, or until June 24, 2013, to regain compliance. If at any time within the grace period the Company’s common stock closes at or above $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Stock Market will provide the Company with a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with the Rule prior to the expiration of the grace period, the Company may request a hearing from a Nasdaq Listing Qualifications Panel, which will stay the delisting and allow the Company to present its plan to regain compliance. In addition, the Company may also be eligible for an additional 180-day grace period if at such time it meets the initial listing standards for listing on the Nasdaq Capital Market, with the exception of the bid price requirement.
Have to take into account float is only @6m. Volume thus far only 130,000.
Resistance is part of chart analysis is it not? Looking told some long term. May did dip a touch on Monday and if it does will add.
The "d" is now removed. Waiting on volume/news.
Resistance points on chart? On phone today. Think 2.79 then?
Link is on bottom of my post
Should see nice bounce next few trading days. Looking for 15%.
http://ir.venaxis.com/2013-05-30-Venaxis-Closes-Underwritten-Public-Offering-Including-Full-Over-Allotment